Cytokines d’origine adipocytaire, obésité et développement du diabète
- 15 August 2003
- journal article
- review article
- Published by EDP Sciences in médecine/sciences
- Vol. 19 (8-9) , 809-817
- https://doi.org/10.1051/medsci/20031989809
Abstract
Normal metabolic balance is maintained by a complex homeostatic system involving multiple tissues and organs. Acquired or inherited defects associated to environmental factors in any part of this system can lead to metabolic disorders such as the syndrome X which is presently a frequent syndrome in industrialized countries. It is characterized by a cluster of risk factors of atherosclerosis including insulin resistance, hyperinsulinemia, impaired glucose tolerance or type 2 diabetes, hypertension, dyslipidemia, and coagulation abnormalities. Its pathophysiology is likely to involve insulin resistance at the level of both skeletal muscle and visceral adipose tissue and altered fluxes of metabolic substrates between these tissues that in turn impair liver metabolism. Therapeutic intervention favours at present diet and exercise prescriptions. In addition, if necessary, specific treatment of the metabolic disorders is required. In the treatment of insulin resistance, new promising drugs are likely to be used in the next future. In this regard, adipose tissue, once thought to function primarily as a passive depot for the storage of excess lipid, is now understood to play a much more active role in metabolic regulation, secreting a variety of metabolic hormones and actively functioning to prevent deleterious lipid accumulation in other tissues and to modulate the insulin resistance. Here, we review new advances in our understanding of mechanisms leading to insulin resistance and type 2 diabetes from the perspective of the role and interactions of recently identified adipocyte-specific chemical messengers, the adipocytokines, such as adiponectin, tumor necrosis factor-alpha, interleukin 6, and resistin.Keywords
This publication has 37 references indexed in Scilit:
- Disruption of Adiponectin Causes Insulin Resistance and Neointimal FormationJournal of Biological Chemistry, 2002
- Adiponectin and development of type 2 diabetes in the Pima Indian populationThe Lancet, 2002
- Plasma Adiponectin Concentration Is Associated With Skeletal Muscle Insulin Receptor Tyrosine Phosphorylation, and Low Plasma Concentration Precedes a Decrease in Whole-Body Insulin Sensitivity in HumansDiabetes, 2002
- Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and HyperinsulinemiaJournal of Clinical Endocrinology & Metabolism, 2001
- Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived MacrophagesCirculation, 2001
- Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent PathwayCirculation, 2000
- Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophagesBlood, 2000
- Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Isolation and Characterization of GBP28, a Novel Gelatin-Binding Protein Purified from Human PlasmaThe Journal of Biochemistry, 1996
- A Novel Serum Protein Similar to C1q, Produced Exclusively in AdipocytesJournal of Biological Chemistry, 1995